StockDuty ← Dashboard Sep 09, 2026 03:15 AM ET
SignalCorporate

InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China

Approval of novel bispecific ADC ICP-B381 marks clinical milestone for InnoCare in China.

What changed
Approval of novel bispecific ADC ICP-B381 marks clinical milestone for InnoCare in China.
Why it matters
Approval of novel bispecific ADC ICP-B381 marks clinical milestone for InnoCare in China. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →